Galapagos NV (GLPG) has released an update.
Galapagos NV is presenting promising preliminary data from their Phase 1/2 studies on innovative CAR-T therapies, GLPG5101 and GLPG5201, at the EBMT congress 2024. These therapies are being tested for hematological cancers such as non-Hodgkin lymphoma and chronic lymphocytic leukemia, showcasing a rapid seven-day vein-to-vein time due to their unique decentralized manufacturing platform. The company aims to improve the treatment experience and outcomes for patients with rapidly progressing cancers.
For further insights into GLPG stock, check out TipRanks’ Stock Analysis page.
